MLYS
Mineralys Therapeutics, Inc.
$27.52
+0.81
(+3.03%)
Mkt Cap
1.82B
Volume
421,709
52W Range
12.59-47.65
Sector
Healthcare
Beta
0.65
EPS (TTM)
-2.05
P/E Ratio
-15.85
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (154.65M) | (177.81M) | (71.90M) | (29.80M) | (19.41M) | (3.43M) |
| EPS | -2.29 | -3.66 | -1.99 | -5.77 | -3.89 | -0.74 |
| Free Cash Flow | (142.43M) | (166.41M) | (81.17M) | (29.22M) | (14.56M) | (2.46M) |
| FCF / Share | -2.11 | -3.43 | -2.24 | -5.66 | -2.92 | -0.53 |
| Operating CF | (142.42M) | (166.31M) | (81.17M) | (29.22M) | (14.56M) | (2.46M) |
| Total Assets | 661.81M | 205.90M | 251.64M | 114.44M | 11.12M | 1.49M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 4.50M |
| Cash & Equiv | 172.92M | 114.09M | 49.30M | 87.70M | 10.61M | 1.41M |
| Book Value | 646.69M | 191.26M | 241.15M | (52.27M) | (22.93M) | (3.60M) |
| Return on Equity | -0.24 | -0.93 | -0.30 | N/A | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (39.34M) | (32.23M) | (36.93M) | (43.27M) | (42.21M) | (48.95M) | (56.34M) | (41.01M) | (31.51M) | (24.39M) | (22.76M) | (12.14M) |
| EPS | -0.47 | -0.40 | -0.52 | -0.66 | -0.79 | -0.98 | -1.13 | -0.83 | -0.70 | -0.61 | -0.57 | -0.31 |
| Free Cash Flow | (39.47M) | (37.90M) | (28.87M) | (30.17M) | (45.49M) | (66.84M) | (50.22M) | (30.15M) | (19.20M) | (28.98M) | (19.03M) | (20.39M) |
| FCF / Share | -0.48 | -0.47 | -0.41 | -0.46 | -0.86 | -1.34 | -1.01 | -0.61 | -0.43 | -0.72 | -0.48 | -0.51 |
| Operating CF | (39.47M) | (37.89M) | (28.87M) | (30.17M) | (45.49M) | (66.84M) | (50.19M) | (30.15M) | (19.14M) | (28.98M) | (19.03M) | (20.39M) |
| Total Assets | 652.86M | 661.81M | 599.95M | 335.72M | 354.94M | 205.90M | 268.25M | 318.49M | 347.25M | 251.64M | 277.56M | 291.22M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash & Equiv | 112.78M | 172.92M | 217.60M | 101.79M | 165.01M | 114.09M | 97.27M | 67.86M | 90.42M | 49.30M | 86.30M | 101.14M |
| Book Value | 638.14M | 646.69M | 576.43M | 313.55M | 341.56M | 191.26M | 236.93M | 290.10M | 328.05M | 241.15M | 264.01M | 285.01M |
| Return on Equity | -0.06 | -0.05 | -0.06 | -0.14 | -0.12 | -0.26 | -0.24 | -0.14 | -0.10 | -0.10 | -0.09 | -0.04 |
MLYS News
What a $350,000 Insider Sale Might Mean for Mineralys Ahead of December FDA Decision
Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)
Mineralys Therapeutics, Inc. (MLYS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)
Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock
Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing
Mineralys' pill cuts blood pressure in kidney disease patients
Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)